Docusign Envelope ID 42E7C64E-386944C1-8361-66ED4F05CE20
PWlrolA¢fvocury & Referrul se￿
ANNUAL REPORT
& FINANCIAL STATEMENTS
For the Year Ended
31 December
2025
One Call. Expert Support. Better Outcomes.
Registered Charity Number- 1152340

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD 1 2025
REFERENCE &
ADMINISTRATIVE DETAILS
REGISTRATION
CONTENTS
Registered company no. 08321795
Registered charity no. 1152340
Trustees, annual report
(incorporating thè Dirtetors, Rèport)
>19
REGISTERED OFFICE
Message from the trustees
New BLJrlington House
1075 Finchley Road
London NW11 OPU
2025 at a glan
Our ambition
What we do
TRUSTEES
Networking
Rabbi Hershel Grunfeld
Mr Jacob Herzka
Mr Pin¢has Weinberger
Research
Referrals
Advocacy
10
AUDITORS
Cohen Arnold
New Burlington House
1075 Finchley Road
London NW11 OPU
Diagn05tics
11
Support
12
Fact5 & figures
13
Our specialist divisions
14
BANKERS
Oncology division
15
Metro Bank PLC
Holborn Branch (Head Office)
1 Southampton Row
London WC1 B SHA
Achievement5 & luture plans
16
Support & accountability
17
Goveman￿ & financial review
18
ORGANISATION DETAILS
Ttustees, responsibilitie5 & approval
19
MARS | Medical Advocacy & Referral Service
Unil 15 Grosvenor Way. London E5 9ND
020 3322 8586
www.marsorg.com
mail@marsorg.com
Independent auditorfs report
2(￿24
Stalement of financial activities
25
Stalement of financial position
26
Stalement of cash flows
27
Not8S to the financial stat8m8nts
Thank you
36
MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
A MESSAGE ,.
FROM THE
TRUSTEES
2025 has been another year of meaningful
progress for MARS. Through compassionate
advocacy, practical support and strong
partnerships, we have continued to help
patients and families navigate some of the
most complex medical challenges.
We work closely with leading UK hospitals
and local doctors, connecting patients with
the right specialists and resources at the
right time. This collaboration helps to
improve access to advanced treatments.
ensuring families receive the best POSStble
guidance and care.
Our commitment to research remains
central to our work, We SupFY)rt and promote
innovative medical research and clinical
trials. helping to bring new treatment options
within reach for the patients we supporL
66
Raising awareness is also vital. By sharing
trusted information and real patient stories.
we help more people in our community
understand their options and feel better
prepared when facing a medical crisis.
We help patients and their families
navigate complex medical decisions,
connecting them with the right
specialists and supporting them at
every stage.
None of this would be possible without
the dedication of our supporters. medical
partners and the wider community. Together
W￿ are making a real difference, giving
patients and families hope, knowledge
and a clearer path forward.
MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
2025
AT A GLANCE
01
Stronger links with
UK hospitals and local doctors
We have deepened our relationships with leading
UK hospitals and local dixtors, building trusted
networks that help patients access the right specialists
faster and navigate complex medical systems bwth
confidence ar4J SUP[￿.
02
More health research
and training
We liave suppoited a wider r"aiige of medical researcli
and clinical trials, and helped to fuid specialist training
and knowledge exchange, Ensuring patI￿ts benefit
from th) latest innovations and best practice in care.
il. 4119"
03
Greater awareness
in the community
We have expanded our community outreach,
tharing trusted information through events, schools,
synagogues and dig￿31 channels, so that more people
understand tIE importance of being prepared for a
¥TE￿lia1 crisis aiid kiKw wI￿re lo Lurri lor guidqjflce.
04
More global medical
opinions
We have helped patients obtain expert medical
opinions from world-leading specialists In the UK.
across Europe, the United State5 arld across the globe,
providirvJ access to internat￿nal expertise when
it can make a critical difference.
05
Expanded support
for patients and families
We have provided more ￿rSOnalISed, ongoing
support throughout the medical journey. offering
practical guidance, reassurance and 3 trusted point
of contact for patients and their families when
they need it most.
MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
OUR
AMtIITION
MARS was established in 2012 by Rabbi
Hershel Grunfeld after witnessing the
confusion, stress and uncertainty
families can face following a medical
crisis.
i*
He saw how overwhelming it can be to
navigate complex medical systems,
make urgent decisions and find the right
specialists at a time when families are
already under enormous emotional
pressure.
Today, MARS guides patients and
families through complex medical
situations, connecting them to the right
experts and resources with compassion,
discretion and practical support.
Our ambition is to give
every patient access to the
most advanced care
available, enabling the best
possible outcome.
IA
MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
WHAT
00
Expert guidance.
Practical support.
Better outcomes.
MARS provides a comprehensive range of services to help patients and
families navigate complex medical journeys. We work quickly, discreetly
and compassionately, connecting people to the right experts and resources
when they need them most.
Networking
Research
We connect patient5 arvj famil
with leacling specialists and
centres ol excellence. localty
and internationally, through
our trusted global network.
We research the latest
11 treatments. clinical trials and
medical innovations. providing
up.to.date. evidence-based
information tailored to each
patient's condttion.
Referrals
Advocacy
ooo
We identify arKI facilitate
access to the most appropriate
coiisultants and medical teams,
ensuring patients are seen by
the right experts as quickty
as possible.
We a&4ocate on behalf of
patients and families, hetping
to remove barriers. liaise wtth
healthcare providers and ensu
palients. needs are understoc
and prioritised.
coi
Diagnostics
Support
Wè help arrange and ex￿lte
vital tests, scans and specialist
diagnostic investigations,
ensuring accurate and timpjy
results to inform the best
treatment decisions.
We provide ongoing. personal
supwrt thrwghout the medical
ioumey. offeriro practtcal
guidance. reassurance and
a trusted point of contact
for patients and their families.
RAISING AWARENESS
IN THE COMMUNITY
MARS is comrnitted to faising awareness abwt i
mpNtsrxe of bwng prepared fof a medical crisis. We
educate ttrectynmunity on valL* ofprivale
Insura￿¢, helpiry families U￿tand t￿11 ¢Jptions
¥1 Ihe pwof miTrd il can provKIe.
We also promote wider medical
awareness, sharing trusted
information and reSoUr￿S to
help our community make
infomed decisions about their
health and wellbeing.
MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386944C1-8361-66ED4F05CE20
NETWOR IING
MARS has built strong relationships with
UK hospitals, the NHS, private specialists
and local doctors. creating a trusted network
that ensures patients can access the right
experts and the most suitable care for their
individual needs.
Through these relationships. MARS helps
people find appropriate specialists. obtain
second opinions and timely treatment. with
the support and guidance they need.
Local
Dortors
UK
Hospitals &
Specialists
International
Expertise
Better
Access
Strong relationships
with trusted local
doctors in our
communities
Acce5S to leadirg
NHS arrfl private
specialists across
theUK
Seeking expert
medical opinions
from Europe, the USA
arKI across the globe
Helping patsents
access the right
specialists, secorKI
Opini¢￿s and
timely care
EUROPE
Leading centres
and global expertise
USA
UK
World-renowned
hospitals and
specialists
NHS & t)rivate
GLOBAL
Access to expert
opinions from across
the world
MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386944C1-8361-66ED4F05CE20
RE >EARCH
In-depth medical research is central to the V￿Ork we do.
MARS gathers and reviews medical records, explores
treatment options. seeks global expert opinions and
keeps abreast of emerging developments to provide
the most current and advanced guidance for our patient&
In 2025. we continued to deepen our connections
with UK hospitals and international experts. ensuring
we stay up to date with advances in treatment, ¢linic81
trial4 and special¢￿t kriowl¢d9Cp 40 wc Gun 4UPPQrt
complex and rare cases with the latest evidence
and expertise.
OUR RESEARCH PROCESS
Q 881
Explor•
Seek Expert
Ild Expwtl
We coited ¥rKI review We research ar
We re¥h out to
We SW infeAn*d
Our r•seard) is
In 2025. we
drt•led medical
compa￿ treat1￿nI specialists in the UK
bout emening Particulady ￿luable strenytr*ned our
cord* tsst rLtysuIÈs OPiw)ns, considering arKI internatio1￿Y trÈ8trM)ts, din*al forw*￿tr￿ comFSex global connect¥ons
d reports io build
the most suitable
fof addiiional
lriaLsaThJ the
cws. whère
io furtlier develop
a complrfe pcturfr.
apprts¥hes lor pefspectNes vthen medical adva¢)¢￿ speoalis¢ knovAed9e
our Spec￿1151
exh patlent.
inr)ovatwe
kn￿ledge and
iivtWCJf
esserfiaL
66
My obiding interest in MARS. ond my willingness
to gwe time to it and support it, 15 because it s there
for potient benefit. Irrespective of where someone
lives. where someone comes from or what their
bockground is, they should alwoys have occess to
the best medicol odvice ond the best medicol core.
And becouse that s not olwoys the cose, we need
orgonisotions thot enoble potients to receive that.
To my mind the MARS organisation is exactly thot.
Professor Kevln Harrlngton
Professor of Biological Cancer Therapies
at The Institute of Cancer Research
99
MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
REFERRALS.
MARS connects patients to the right specialists
quickly and sensitively. based on their medical
condition, the expertise required, location,
urgency and the family's circumstances.
Our experienced team works closely with patients, families
and treating doctors to identify the most appropriate specialists
and services. arrange appointments. obtain expert opinions.
coordinate consultations and guide each patient to the most
suitable rr*dical pathway.
HOW WE MAKE THE RIGHT
I IVNS
UNDERSTAND THE PATIENT'S NEEDS
We take time io unuerstand the m¢di¢al conditw,
experttse required location, wgerq and the family&
personal circumstance&
IDENTIFY THE RIGHT SPECIALIST
We match each patient with the most suitable specialist,
based on their specific condition, experience and access lo
the latest Irealments.
ARRANGE APPOINTMENTS
We liaise directly with spechllists and hospitsls to
. secure timely appointments. ofien expediting access
' when urgenl care Is fequired.
OBTAIN EXPERT OPINIONS
We help palients access second opinions and
multtd55ciplinèry input when needed. providing
confidence in their diagnosis and ireatment options
COORDINATE THE PROCESS
The right
specialist.
At the right time.
For the best
possible outcome.
We manage communication between patients, specialists
and hospitals. ensuring Information is shared, ￿$￿Its are
obtained and consuliations are wdl cO￿dinated.
GUIDE TO THE BEST PATHWAY
Wo Iiravide cloai. nl)Jèctive giJi(lance to Ihe most suitable
medKal pathway. wheiher that invdve5 further testing.
specialist irealff￿t. suryJery or oryoing cafe.
MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
ADVOCACY I
MARS supports, informs and empowers
patients and families at every step, helping
them understand their options, navigate
complex systems and feel confident in
the decisions they make.
Our team wovides clear, impartial information and practical
direction. ensuring patients can ask informed questions,
communicate effectively with medical providers and access
the support they need throughout their healt￿are journey.
HOW WE SUPPORT
rr
ILIES
CLEAR. RELIABLE INFORMATION
We explain medical conditions, tr&atmwt options and
next steps in plain language, so patients and families
can make informed decisions.
SUPPORT AT EVERY STEP
We are here to Ilsten. answer questions and provide
reassurance frorn the first call through to treatment
nd beyond.
66
It is o privilege to work
with Rabbi Grunfeld and
MARS. I have always found
that MARS is committed to
providing the highest standard
of care. They support f(7milies
at a time of need when there
can be great anxiety and
uncertainty. Rabbi Grunfeld
takes time to understand the
complexities of each individual
case to be able to provide
insightful advice cnd guidance.
HELP YOU ASK THE RIGHT QUESTIONS
le help palionts prepare lor COnSLltations, with guidarte
on the questicms to ask and the informatK)n to request
NAVIGATE COMPLEX SYSTEMS
le explaiii how the IEalthcare systeNI works, hdp with
referrals and reoire the barriersthat can de￿Y acce55 to Core.
ADVOCATE ON YOUR BEHALF
We commUn￿te with medical providers. ensure patient
needs are understood and help resolve issues when
additional SUPFX)rt is required.
GUIDANCE FOR COMPLEX DECISIONS
le proijide IndependLI"It, expert advice vvlien lacing
difficult choices. helping patients consider risks, benefits
and alternative opti¢y15.
Mr Pranav Pandya
Consultant in Fetal Medicine,
Director of Fetal Medicine, UCLH
HOSPITAL COORDINATION
We liaise with h05Pltals and specialist team5 to keep
treatment on track, coordinate appthntments and ensure
a smooth pathway of care.
MARS I ANNUAL REPORT 2025
10

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
DIAGNOSTICS,,
Faster answers. The right support.
A clearer path forward.
MARS helps patients access urgent diagnostics, spectalist
consultations and the assessments they need, when they
need them. We work to remove barriers, including providing
financial assistance where necessary, to ensure patients can
access essential investigations and stabilize their path
to treatment.
Through rapid access and expert review. we help patients
get answers faster. enabling them to make informed
decisions and move forward with clarity and confidence.
URGENT
DIAfjN05TICS
SPECIALIST
A55E55MENT5
Rapid ac￿5 to essentiaE
scans. tests afK* investigatic￿S
wlien time mattefs most.
Comprehensive assessments
to confim diagnosis and
guide treatment option
SPECIALIST
CONSULTATIONS
FINANCIAL
ASSISTANCE
A£￿5$ to leading specialists
across a wide range of
rnedical condttions.
Support with costs where
needed. helping patients
access vital investigations
and services.
EXPERT REVIEW
A CLEARER PATH
FORWARD
Independent review of results
and repyts to ensure the r¥Jht
diagrmxis aKI next st
Helping patients move ahead
with clarity. confidence and
the right support in place.
MARS I ANNUAL REPORT 2025
11

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
-SUPPORT
Patients. Families. Always alongside.
MARS supports patients and their families throughout the
entire journey. From the first call to ongoing care, we provide
emotional support, practical direction and coordination
help, ensuring no one has to navigate complex medical
challenges alone.
EMOTIONAL SUPPORT
A listening ear and compassionate
guidance for patients and families
during challenging times.
PRACTICAL DIRECTION
Clear, trusted information to help
families understand options and
make confident decisions.
ONGOING CONTACT
Regular check-ins and continued
support, so patients and families
never feel alone.
COORDINATION SUPPORT
Helping to link appointments,
share information and work with
providers for a smoother journey.
AWARENESS
MARS helps raise awareness of private
medical insurance and other important
rnedical issues in the community, so
families can stay inf0m￿d and up to date.
Trusted
Information
Community
Education
Keeping
Families Informed
MARS I ANNUAL REPORT 2025
12

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
FACTS & FIGURES
In 2025, MARS continued to make a real difference, ensuring
more patients received the urgent diagnostics and specialist
consultations they needed, when they needed them.
300 30
Calls every day
Resolute
staff
11 3,461
17
402
New cases
in 2025
Medical
divisions
Emergency diagnostics
and consultations
funded
12
••.
Oncology
divisions
One Ca//.
Expert Support.
Beffer Outcomes.
MARS I ANNUAL REPORT 2025
13

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
OUR
SPECIALIZED
DIVISIONS
MARS funds emergency diagnostics. consultations and treatment
across a wide range of medical specialties. ensuring patients have
fast access to expert care when it matters most.
Cardiology
Complex
Pediatrics
Critical Care
Dermatology
Endocrinology
ENT
Fetal
Medicine
Gastroenterology
Hematology
Neurology
OB-GYN
Ophthalmology
Orthopedics
Renal &
Urology
Respiratory
Rheumatology
Surgical
MARS I ANNUAL REPORT 2025
14

Docusign Envelope ID". 42E7C64E-386944C1-8361-66ED4F05CE20
ONCOLOGY
DIVISION
EXPERT GUIDANCE. ADVANCED CARE.
BEThER OUTCOMES.
Oncology is a major and specialist division within MARS,
providing expert care for a wide range of cancers and
complex conditions. We bring together leading specialists to
offer advanced diagnostics. personalised treatment plans,
second medical opinions. and coordinated care across our
network.
Our work includes cutting-edge research, access to
innovative treatments. and ongoing support for patients and
their families. Through close links with UK hospitals and
international medical experts, we help ensure every patient
receives the right guidance, at the right time, wherever they
are in their cancer journey.
12 ONCOLOGY DIVISIONS
Breast
Oncology
Gastrointestinal
OnGology
Neuro-oncology
Dematologic
Oncology
Gynecologic
Oncology
Ocular
Oncology
Hematologic
Oncology
Head and Neck
Oncology
Pediatric
Oncology
Soft Tissue and
Sarcoma Oncology
ThoraGiG
OnGology
Urologic
Oncology
Specialist care. Global expertise.
Support for patients and families.
MARS I ANNUAL REPORT 2025
15

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
2025 ACCOMPLISHMENTS
In 2025, MARS made significant progress in oncology and across
our wider work, helping more patients access expert care and support,
and continuing to advance research and innovation.
STRONGER LINKS
WITH UK HOSPITALS
MORE RESEARCH
AND TRAINING
GREATER AWARENESS
IN THE COMMUNITY
Buslt closer relationships
with leading UK hospitals
and local doctors to
improve access to specialist
care and faster pathways
for patients.
Expanded cancer research
activity and provided more
specialist training for
doctors and healthcare
professionals.
Increased awareness
about cancer and the
medical needs of patients
through community
engagement and
education.
EXPANDED PATIENT
AND FAMILY SUPPORT
SOFTWARE UPDATES
AND DATA PROTEcfioN
Continued to enhance
our systems and software
to meet modern healthcare
needs and improve
patient support and
Case Coordination.
MORE GLOBAL
MEDICAL OPINIONS
Strengthened practical.
emotional and informational
support for patients
and their families at
every stage.
Supported more
international medical
opinions where needed.
helping patients access
world-leading expertise
and tr•atment options.
LOOKING AHEAD 2026-27
We will continue to build on this progress. with a clear focus on expanding
our oncology work and further strengthening the support we provide.
CONTINUED
DEVELOPMENT
OF ONCOLOGY
RESEARCH
INTO GENETICS
DEEPER CARDIAC
OEVELOPMENT
STRONGER
SUPPORT SERVICES
ONGOING
somvARE UPDATES
CortiNe to athance
tyjr cardiJ¢ work
lo yjpport palients
with compFex c8ncer
and cardiovascular
Keop deN*lo5Yry
Our Systems and
tec1r￿o9Y lo enhance
patient supp)rt.
data proiection and
case coordinatio
GTQIV &nd
FurthAr strnFv3th•n
0￿0￿)Y dlvi5ion
research into cancer
to ieath rr￿e patsents
genet￿5 and
d Ixitc¢)rres ￿rsOnalIsed treatment
¥pproache&
Enh￿e the raTh
of services for pabents
and famil￿ wtih
focus ￿ efWti(x￿I
MARS I ANNUAL REPORT 2025
16

Docusign EnvelopÈ ID". 42E7C64E-386944C1-8361-66ED4F05CE20
CONTINUED SUPPORT
& ACCOUNTABILITY
l Ded
icated caseworkers
omplex cases and clinical trials
Cases involving several teams or limited conventional
options may require wider research, multiple opinions,
multidisciplinary planning and exploration of
appropriate clinical trials.
Long-temi and complex cases can require sustsined
contsct. MARS assigns caseworkers lo help families
navigate appointments, decisions, communications
and ongoing Care.
ospital liaison and urgent advocacy
Hospital emergencies do not follow office hours.
MARS has described round-lhe-clock support, liaison
with medical teams and advocacy for patients with
medical, cultural and practical needs.
Interpretation and cultural understanding
MARS helps explain complex terminology, address
language barriers and communicate individual
religious and cultural requirements to healthcare
professionals.
Medical records and technical guidance
The team helps families request previous scans, lest
results and medical reports, and navigate patient
portals, remote consullalions, digital fomis and
information sharing.
om-Tov clinics
Free, urgent GP walk-in SeNi￿S for Yom Tov in
Stamford Hill and Golders Green.
ransfers and practical coordination
For patients needing care al another hospital or
overseas, MARS helps coordinate medical and travel
arrangements, clinical handovers and associated
logistics where appropriate.
ommunity education and training
The estsblished programme includes private medical
insurance awareness, wider health information,
professional learning, medical conferences and
community medical training.
iagnostics and financial assistance
In selected urgent or potentially life-threatening
cases, MARS has helped patients access private
investigations or specialist opinions while also
coordinating ongoing NHS care.
Evaluation and feedback
Feedback from patients, medical professionals and
community leaders helps MARS refine ils work.
Complaints, queries and feedback are recorded
sensitively, recognising patient privacy and the
pressures of illness.
MARS I ANNUAL REPORT 2025
17

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG LTD
TRUSTEES, ANNUAL REPORT. YEAR ENDED 31 DECEMBER 2025
STRUCTURE, GOVERNANCE AND MANAGEMENT
Governing document
The ¢h)riiy is controlled by its governing document, its memorandum and articles of associatiL)n, and constitutes a limited
company, limit¢d by guarant¢¢, as d¢fin¢d by Companics A¢t 2006.
Recruitment and appointment of new trustees
It is not currently the intention of the trustees of the charity to appoint new trustees. Should this situation change in the
future, the trustees will apply suitable recruitment and training procedures.
Risk Management
The trubtees have identified and reviewed the major risks to which the charity is exposed, in particular those related to the
operations and finance of ihe charity, and are saiisfied that systems are in place to mitigate ihose risks.
Publlc beneflt
Tlie tTUStees confiTm that they hdve iefetred to the ¥uiddnce Lontrdined in the Chdtity Cuminission's general ¥uiddrice ori
public benefit. when reviewing the charity's aims and objectives, and in planning future activities and setting grant making
policy for the year.
MARS selves people fiom ethnic ininority cominui)ities, ftscusing paiticularly, but not exLlusively, on the Orthodox Jewish
Community. This community has unique religious and culrural needs that may be unfamiliar to the medical world. This
community also includeg recent immigrants to the UK, meaning that both the language and the culture are unfamiliar to
thcm.
Geographically, we are based in London, but we receive calls from all over England and have liaison officers located in
other areas of the UK such as Essex, Manchester and Gateshead.
FINANCIAL REVIEW
The financial position of the Charity is satisfactory.
Incoine and donations aggtegate £1,728,031. Total resouiLes expended were £1,727.803 resulting in a net surplus of £228
for the year and toial reserves of £384.258 (2024.. £384,030).
DuTiil¥ the year, the LhaTity expetienced a peri(Id of heightened S¢￿tinY following a ChaTity Coinmi55ion enquiry. The
enquiry concluded in March 2026 with eertain recominendations made which the Trustees are now addressing.
FuMdr#isiMg Campaign
Tlie charity held a fundraising campaign in July 2025. Some pledged donations had not been received by 31 December 2025,
and receipts froin the CdlllP(ii¥n continued ii)to 2026.
Reserve5 policy
The Trustees have examined the charity's requirements for rese￿eS in light of the mait] risk5 to the organisation. It has
e5tabli5hed a policy whereby the unrestricted funds not cominitted or invested in taiibTible fixed assets held by the charity
should be between 3 and 6 months of the expenditUTe. Budgeted expendituie for 2026 is £1.2m and therelort the target is
£300,000 to £600,0(10 in unrestricted reserve funds. The reserves are needed to meet the working capital requirements of the
charity and the Management Committee are confident that at this level they would be able to continue the current actii'ities
of thc charity in thc cvcnt of a significant drop in funding. Thc prcscnt Icvcl of unrcstrictcd rc8crvc% availablc to thc charity
of £284,000 therefore falls short of thi5 tsrget level.
MARS I ANNUAL REPORT 2025
18

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG LTD
TRUSTEES, ANNUAL REPORT. YEAR ENDED 31 DECEMBER 2025
TRUSTEES. RESPONSIBILITIES STATEMENT
The trustees, who are also directors for the purposes of company law, are responsible for preparing the trustees, report and
the financial %tatcmcnts in accordance with applicablc law and Unitcd Kingdom Accounting Standard% (United Kingdom
Generally Accepted Accounting Practice).
Company law requires the eharity trustees to prepare financial statements for each year which give a true and fair view of the
state of affair5 of the charitable company and the illcoming resources and application of resources, including the income and
expenditure, for that period.
In prcparing thc%c financial %tatcmcnt8, thc tru%tcc% arc rcquircd to..
select suitable accounting policies and then apply them consistently,.
observe the meth(Kls and principles in the applicable Chaiities SORP.,
ake judgments and accounting estin￿teS that are reasonable and prndent-
prcparc thc financial.%tatcmcntq on thc going conccrn ba8i% unlc$8 it is inappropriatc to prcsumc that thc charity will
contit]ue in business.
The trustees are responsible for keeping adequate accounting re¢ords that are sufficient to show and explain the charity's
transactions and disclose with reasonable accuracy at any time the financial position of the chaTity and et]able them to ensure
that the financial sthtements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of
the Ch[￿ltY aiid hence foi takin¥ reabunable steps foi the prevention aiid detectiun of Iiuud aiid Other itTe¥ulL￿lt]cS.
In so far as the trllstees are aware..
there is no relevant audit inforniation of which the charitable company's auditors are unaware., and
the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit infom)ation
and to estsblish that the auditors are aware of that inforniation.
The auditors, Cohen Amold were appointed on 27 October 2025 and will be proposed for re-appointment at the forthcoming
Annual General Meeting.
AUDITOR
Each of the persons who is a trustee at the date ol'approval of this report confim)s that".
50 far a5 they are aware, there 15 no relevant audit infolynation of which the charity'5 auditor is unaware.. and
they have taken all steps that they ouglit to haN'e taken as a trustee to make themselves aware of any relevant audit
infom]ation and to establish that the charity's auditor is aware of that infoTmation.
Thc auditor 1% dccmcd to havc bccn rc-appointcd in accordancc with %cction 487 of thc Companics Act 2006.
SMALL COMPANY PROVISIONS
This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies
cxcmption.
2911012026
The twstees, annual report was approved on .............................. and signed on behalf of the board of trustees by..
Mr H Giunfeld
gn•d by..
Trustee
b82cl764E￿24A5
MARS I ANNUAL REPORT 2025
19

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MARS ORG. LTD
YEAR ENDED 31 DECEMBER 2025
OPINION
We have audited the financial statements of MARS ORG. LTD (the 'charit) ) for the year ended
31 December 2025 which comprise the statement of financial aCtI￿.1t]eS (including income and
expenditure account), statement of financial position, statement of cash tlow's and the related notes,
including a summary of significant accounting policies. The financial reporting framework that has been
applied in their preparation is applicable laiv and United Kingdoin Accounting Standards, including
FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland {United
Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements..
give a true and fair i'iem, of the state of the charity's affairs as at 31 Deceinber ?025 and of its
incoiniiig rcsources and application of resources. including its incoine and expcnditure, fort]ie }'ear
then ended;
have been properlv prepared in accordance with United Kingdom Generally Accepted Accounting
Practice-
havc bccn prcparcd in accordance with th¢ requirctncnts of the Cotnpanics Act 2006 and the
Charities Act 2011.
BASIS FOR OPINION
W¢ ¢ondu¢led our audit in a¢cordaiice witli Intemalional Standards on Auditing {UK}{ISAs (UK)} and
&ppli¢able law. Our responsibilities under tliose standards are fiirtlier described in the aiiditor's
resw)nsibiliii¢s for the audit of the finan¢ial slatem¢nis section of our report. We are ind¢p¢ndent
of the charity. in accordance with the ethical requirements that are relevant to our audit of the financial
statements in the UK, including th¢ FRC s Ethi¢al Standard, and w¢ hav¢ fulfilled OLir other ¢thi¢al
reswnsibiliiies in accordance with these requireinents. We believe that the audit evidence we have
obtained is sufficient and appropria(e to provid¢ a basis for our opinion.
CONCLUSIONS RELATING TO GOING CONCERN
In auditiiig the financial statements, Ive have concluded that the ti'ustees, use of the going concern basis
of accounting in the preparation ot the financial statements is appropriate.
Based on the workwe have perfom]ed, we have not identitied an}, material uncertainties relating to eiwents
or conditions that. individually or collectiiwely, ma}, cast significant doubt on the Compan￿ s ability to
continue as a going concern for a period of at least twelve months from ivhen the financial statements
are authorised for issue. Our responsibilities and tl)e respx)nsibilities ot the trustees with respect to
goiiig coiiccrn are described in the rclcvant sections of this rcpx)rt.
MARS I ANNUAL REPORT 2025
20

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MARS ORG. LTD
YEAR ENDED 31 DECEMBER 2025
OTHER INFORMATION
The other infom]ation comprises Ihe infom)ation included in the annual report, other than the financial
statements and our auditor's report thereon. The trustees are responsible for the other infom)ation.
Our opinion on the financial statements does not cover the other infom)ation and, except to the extent
otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the other
information and, in doing so, consider whether the other information is materiall)w inconsistent with the
financial stateinents or our knoivledge obtained in the audit or otheThi'ise appears to be materially
tlllSStated. If ive identify such material inconsistencies or apparent material misststetnents, we are
required to determine ￿'hether there is a material Iiiisstatement in the financial statements or a material
tlllSStatcmellt of the otlier inforniation. If, based on tl)e work we have perfotincd, concludc that
there is a material tnisstateinent of this other infotination, we are required to report that fact.
We have nothing to report in this regard.
OPILYIOIYS OLY OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006
In our opinion, bascd on the work undcrtakcn in th¢ course of th¢ audit..
the information given in rhe trustees, report for tlie fiiian¢ial year for whicli the financial
statements are prepared is consistent with the financial stateiiients; and
the trustees, report has been prepared in accordance with appli¢able legal reqiiirements.
MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION
In (he light ofthe knowl¢dgeand understanding of the charity and its environmentobtained in the Course
of the audit, we have not identified material misstatements in the trustees, report.
We have nothing to re]x)rt in respect of the follo￿.]ng matters in rela(ion to which the Companies Act
2006 and the Charities Act 201 I requires us to report to )'ou if, in our opinion..
adequate accounting records haN'e not been kept, or retums adequate for our audit have not been
received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of irustees, remuneration specified by laiv are not made,. or
we have not received all the infom]ation and explanations we require for our audit; or
the trustees were Iiot eiititled to prcpare the finaiicial statctnciits iii accordaiice w'ith thc small
coinpanies regitne and take advanlage of the sinall companies, exeiiiptions in preparing the
director5, report and from the requiretnent to prepare a strategic report.
MARS I ANNUAL REPORT 2025
21

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MARS ORG. LTD
YEAR ENDED 31 DECEMBER 2025
RESPONSIBILrrIES OF TRUSTEES
As explained more fully in the trustees, responsibilities statement, the trustees (who are also the
directors for the purposes of company law) are responsible for the preparation of the financial
statements and for being satisfied that they give a true and tair view, and for such internal control as the
trustees detem)ine is necessary to enable the preparation of financial statements that are free from
material misstatement, whether due lo traud or error.
In preparing the financial slatements, the trustees are responsible for assessing the charity's ability,
to continue as a going concern, disclosing, as applicable, matters related io going concern and using
the going concern basis of accounting unless the trustees eiiher intend to liquidate the charity or to
cease operations. or have no realistic alternative but to do so.
AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FIIYANCIAL STATEMETr4TS
Our objectives are to obtain reasonable assurance aboutwhetherthe financial statements a5 a whole are
frcc from matcrial misstatcinciiL whcthcr duc to fraud or crror. and to Issuc an auditor s report that
includes our opinion. Rcasonablc assurance 15 a high level of assurance. but is not a guarantee that an
audit conducted in aLcordance with ISAS {UK} will aliva)'s dctcct a matcrial misstat¢tn¢nt whcn it
exisls. Missiatemenls cali arise from fraud or error aiid are considered material if, individuall). or in the
&ggregat¢, they could rcasonably be expccted to influence the ecoiioinic decisions of uscrs taken on
rhe basis of these financial statements.
Irregulariiies, including fraud, are instances of non-¢omplian¢e wilh laws and regulations. We design
procedures in line with our respoiisibilities, oiitlined above, to detevl material misstalemeiits in respect
of irregulariti¢s, including fraud. Th¢ ext¢ni to which our pro¢¢dur¢s are ¢apable of det¢ciing
irregularities, including fraud is detailed beloiv..
We obtained an understanding of the legal and regulatory frameworks that are applicable to the
company, and deterniined that the most relevant to the presentation of the financial statements are those
that relate to the reporting legislation (UK GAAP and the Companies Act 2006), the relevant tax
regulations in the United Kingdom, the Landlord and Tenant Act, the UK General Data Protection
Regulation (GDPR), Health & Safety Regulations and the Bribery Act. We understood ho￿. the company
is complying ivith those frameworks through disciissioii ivith the trustees and senior management, and
by identify'ing the company's policies and procedures regarding compliance with laTh's and regulations.
We also identified those members of management ivho l)ave tlie primary respoiisibility for ensuring
compliance with laws and regulations, and for reporting an}, known instances of non-compliance to the
trustees. We communicated tl)ese identified fraiiiew'orks aii)ongst our audit teain and remained alert
to any indications of non-compliance throughout the audit. We ensured that the engagement teatn had
sufficientcotnpetenceand capability to identify or recognise non-compliance with law's and regulations.
We discussed with the trustees and senior managemenl the policies and procedures regarding
cotllpliaiicc M'ith th¢sc Icgal and regulatory fratncworks.
W¢ asscsscd thc susccptibilitv of the coillpany's financial statcmellts to Inaterial mis5tatcinent,
including how fraud tnighi occur, by reviewiiig the cotnpan} s idcntified risks and enquiry with ihe
trustccs and senior maiia¥cin¢nt during thc planning and finalisation phas¢s of our audit. Thc
susceptibility to such material misstaleinent was detemiined to be low.
MARS I ANNUAL REPORT 2025
22

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MARS ORG. LTD
YEAR ENDED 31 DECEMBER 2025
Based on this understanding we designed our audit procedures to identify non-compliance with the
identified legal and regulatory frameworks, which ￿'ere part of our procedures on the related financial
statement items. Our procedures included reviewing the company's internal controls policies and
procedures, re￿.leThing the minutes of board meetings and correspondence with regulatory bodies
includiiig HMRC, testing trai)sactions outside the normal course of the business and journal entries, and
discussions with the trustees and senior management.
Owing lo the inherent limitations of an audit, there is an una￿0]dable risk that we tnay not have detected
some Inaterial Inisstatements in tlie financial stateinents, even though we have properl). planned and
performed our audit in accordance with auditing standards. For exatnple, the further retnoved non-
cotnpliance with laws and regulations (irregularities) is from the events and transactions reflected in
the financial statements, thc Icss likcly the iiihcrcntl). litnitcd procedures required by auditing standards
would identify it. In addition, as with any audit, there remained a higher risk of non-detection of
irrcgularitics, as tlicsc may involvc collusion, forgery., intentional oinissions, misrcprescntations, or thc
override of intcrnal controls. We are not responsible for preventing non-cotnpliance and cannot be
cxpcctcd to dct¢ct iion-coinpliancc with all laws and regulations.
As part of an audit in accordanc¢ with ISAS (UK), we cxcrcisc profcssional judgtllent and maintain
professional scepticisin throughout the audit. We also:
Ideiilify and assess tlie risks of material misstatemeiil of the fiiiaii¢ial starements, whetlier due to
fraud or etTor, design and perforin aiidit prc)cedures respc)nsive to those I'isks, and obtain audit
evid¢n¢e that is sutTi¢ienl and appropriat¢ to provid¢ a basis for our opinion. The risk of not
detecting a material misstatement resulting from fraiid is higher than for one ￿sUIting from error,
as fraud masj involve ¢ollusion, forg¢ry, inl¢ntional omissions, misrepresentations, or the overrid¢
of internal control.
Obtain an understanding of internal control relevant to the audit in order to design audit procedures
that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
effectiveness of the internal control.
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting
estimates and related disclosures made b}, the trustees.
Conclude on the appropriateness of the trustees, use of the going concern basis of accounting and, b
ased on ihe audit evidence obtained. whether a tnaterial uncertainty exists related to events or
conditions that Inay cast significant doubt on the charity's ability to continue as a going concern. If
we conclude that a material uncertainty exists, we are required to draw attention in our auditor's
report to the related disclosures li) I1)e financial statetllents or, if such disclosures are inadequate:
to modify our opiiiion. Our conclusions are based on the audit evidence obtsiiied up to the datc
auditor's report. However, future events or conditions may cause the charity to cease to continue
as a going concern.
Evaluatc thc overall preKntatlOll, Structure and colltcnt of thc financial statcmcnts, including thc
disclosure5, and whether the financial stateinents rcpresent the undcrlying transactions and events
in a mann¢r t])at acl)icvcs fair prcscntation.
MARS I ANNUAL REPORT 2025
23

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MARS ORG. LTD
YEAR ENDED 31 DECEMBER 2025
We communicate with those charged with governance regarding, among other matters, the planned
scope and timing of the audit and significant alldit findings, including any significant deficiencies in
internal control that we identity during our alidit.
USE OF OUR REPORT
This report is made solely to the charity's members, as a body, in accordance with section 144 ot
the Charities Act 2011 and regulations made under section 154 of that Act. Our audit w'ork lias been
undertaken so ihat ive might state to the charitv's members those matters we are required to state
to tl)ein in an auditorfs report and for no other purpose. To tlie fullest extent permitted by law, we do not
accept or assutne responsibililv to anyone other than the charity and the charity's members as a body,
for our audit work, for this reporL or for the opinions we have fortned.
Do¢US￿nId ty..
8C6977A458CD499
New Burlington House
1075 Finchley Road
London
NWII OPU
David Goldberg (Senior statutory auditor)
Cohen Arnold
Chartered accountants & statutory auditor
2911012026
MARS I ANNUAL REPORT 2025
24

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
STATEMENT OF FINANCIAL ACTIVITIES
(INCLUDIIYG INCOME AND EXPELNDITURE ACCOUNT)
YEAR ENDED 31 DECEMBER 2025
2025
Restricted
funds Total funds Total fi]nds
2024
Unrestricted
funds
Note
Income and endowments
Donations and legacies
Investment iiicome
1,478,901
1,959
247,171
1,726,072
1.959
1,594,668
1,019
Total income
1,480,860
247,171
1,728,031
1,595,687
Expenditure
Expei)diture on ￿lSing funds..
Cosls of raising donations and
Icgacics
Expenditure on charitable activities
Totll expenditure
(209,744)
(209,744) ( l J9,943)
9,10 11,312,870) (205,189) (1,518,059) {1,4JO,138)
(1,522,614) (205,189) (1,727J103) (1,570,081)
Net income and net movement in funds
(41,754)
41,982
228
25,606
Reconcilialion of funds
Total funds brought form'ard
Total funds earried forward
326,559
57,471
384,030
358,424
284,80)
99,453
384258
384,030
The stat¢menl of finan¢ial activities includes all gains and losses recognised in the year.
All income and expenditure derive from continuing activities.
Th¢ notes Dn pages 28 to 35 fonn part nf these financial sl¢it¢rn¢nLs.
MARS I ANNUAL REPORT 2025
25

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
STATEMENT OF FINANCIAL POSITION
31 DECEMBER 2025
2025
2024
Note
FIXED ASSETS
Tangible fixed assets
CURRENT ASSETS
Debtors
Cash at bank and in hand
16
216281
224.828
17
30,420
184,065
197,883
214,485
197,883
CREDITORS: amounts falling due
within one Year
19
(29J50)
{16,460)
NET CURRENT ASSETS
185,135
181,423
TOTAL ASSETS LESS CURRELYT
LIABILITIES
401,416
406,251
CREDITORS: amounts falling due
after more than one vear
20
(17,158)
{22,221)
NET ASSETS
384258
384,OJO
FUNDS OF THE CHARITY
Restricted funds
Llnreslricled funds
99,453
284,805
57,471
326,559
Total charity funds
21
384258
384,030
These finan¢ial statements have been pr¢par¢d in a¢cordanc¢ wilh the provisions applicable to
companies subject 10 the small companies, regime.
These financial statements were approved by the board of trustees and authorised for issue on
2911012026
, and are signed on behalf of the board by..
S*n•dby'.
riin
Trusfre
Th¢ notes Dn pages 28 to 35 fonn part nf these financial sl¢it¢rn¢nLs.
MARS I ANNUAL REPORT 2025
26

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
STATEMENT OF CASH FLOWS
YEAR ENDED 31 DECEMBER 2025
2025
2024
Note
CASH FLOWS FROM OPERATING ACTIvrrIES
Net income
228
25.606
AdjuslmL)nl.%]or.'
Depreciation of tangible fixed assets
Other interest receivable aiid similar income
Interest payable and similar charges
Changes iii..
Trade and other debtors
Trade and other creditors
8547
(1,959}
1,182
1,716
(1,019)
2,709
{30,420}
12088
49,307
(5.037)
83,282
Cash generated from operatioiis
Interest paid
Interest received
(9,534}
(1,182)
(2,709)
1,019
Net cash (used in)Ifrotll operating activities
(8,757)
81,592
CASH FLOWS FROM INVESTING ACTIVITIES
Purchasc of tangibl¢ assCtS
Net cash used in iiivesting activities
(3,236)
(3,236)
CASH FLOWS FROM FINANCING ACTIVITIES
Pro¢¢¢ds from botTowings
Net cash used in financing a¢tiviti¢s
(5,064)
(5,064)
(4,549)
(4,549)
NET (DECREASE)IINCREASE IN CASH AND CASH
EQUIVALENTS
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR
{13,821}
197083
73.807
124.076
CASH AND CASH EQUIVALENTS AT END OF YEAR
18
184,062
197.883
Th¢ notes Dn pages 28 to 35 fonn part nf these financial sl¢it¢rn¢nLs.
MARS I ANNUAL REPORT 2025
27

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMEINTS
YEAR ENDED 31 DECEMBER 2025
GENERAL INFORLIL4TION
The charity is a public benefit entity and a private compan}, limited by guarantee, registered in
England and W'ales and a registered cliarity in England and Wales. The address ot the registered
office is New Burlington House. 1075 Finchley Road, London, NWI I OPU, United Kingdom.
STATEMENT OF COMPLIANCE
These financial statements have been prepared in compliai)ce witl) FRS 102, 'The Fii)ai)cial
Reporting Standard applicable in the UK and the Republic of Ireland,, the Statement of
Recommended Practice applicable to charities preparing their accounts in accordance with the
Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities
SORP {FRS 102)) and the Companies Act 2006.
ACCOUNTING POLICIES
BASIS of preparation
Thc financial statcmcnts havc bccn prcparcd on the historical cost basis.
Thc financial statements arc prcparcd in stcrlin¥y which is the functional currency of th¢ entity.
Going concern
There are no mat¢rial uncertainties abour rhe ¢harity's ability to Continue.
Judgements and key sources of estimation uncertainty
The preparation of th¢ finan¢ial stat¢m¢ntq r¢quires man&g¢m¢nt to make judgements, ¢stimates a
assiimptions that affect the amounts reported. These estimates and judgements are continually
reviewed and are based on experience and other factors, including exp¢ctations of future ¢v¢nls
that are believed to be reasonable under the circumstances.
There have been no material adjustments based on estimations and assumptions during the financial
year.
Fund aceounting
General unrestricted funds comprise the accurllulated surplus or deficit on incoine and expenditure
account. Thev are available for use at the discretion of the Trustees in furtherance of the general
objectives of the Charity.
Restricted funds are funds subject to specific restricted conditions imposed by donors.
Dc5ignatcd funds arc funds which have bccn sct at thc di5crction of the Trustccs for specific purposes.
Therc are no designated funds as at the Balance Sheet date.
Incoming resources
All donations arc rccognis¢d in thc statcmcnt of financial activitlcs (SOFA} of thc charity whcn
received. All other income is recognised on a receivable basis.
MARS I ANNUAL REPORT 2025
28

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿?
YEAR ENDED 31 DECEMBER 2025
ACCOUNTING POLICIES {cortiiniied)
Resourees expended
All expenditure is classified urider the Charity's principal categories of charitable and other
expenditure and by the type of expense.
Tangible assets
Tangible assets are initially recorded al cost, and subsequently stated at cost less any accumulated
depreciation and iinpairment losses. Any tangible assets carried at revalued aii)ounts are recorded
at the fair value at the date of revaluation less any subsequent accutnulated depreciation and
subseqiient acciimulated iiiipairment losses.
An increase in the catrying ainount of an asset as a resiilt of a revaliiation, is recognised in other
recogni5ed gains and 105ses, unless it reverses a charge for iiiipairtnent t]iat has previously been
recognised as expenditure within the statement of financial aclivities. A decrease in the carrying
amount of an a5SCt as a result of rcvaluation, is rccogniscd in othcr rcco¥niscd gains and Iosscs,
except lo which it offscts anj. previous revaluation gain, in which c&se the loss is shown i¥ithin other
recognised gains and losses on the statcmcnt of financial activities.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value,
over the us¢ful economi¢ life of that asset as follows..
Fixlur¢s and filliiigs
Coinputer equipment
FinaDeial instruments
15 % r¢ducin£ balanc¢
330/0 reducing balance
A financial asset or a financial liability is recognised only when the entit! becomes a party to the
contractual provisions of the insirument.
Basic financial instruments are initiall)w recognised at the amount receivable or payable including
any related transaction costs, unless the arrangement constitutes a financing transaction, w,here it
is recognised at the present value of the future payments discounted at a market rate of interest for
a similar debt instrument.
Ciirrent assets and current liabilities are subsequently tneasured at the cash or other consideration
expected to be paid or received and not discounted.
LIMITED BY GUARANTEE
The charity is a company limited by guarantee and has no share capital. The liability of each ttwstee
in thc cvciit of winding up is litllitcd to £ l.
MARS I ANNUAL REPORT 2025
29

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿?
YEAR ENDED 31 DECEMBER 2025
DONATIONS AND LEGACIES
Unrestricted
Funds
Restricted Total Funds
Funds
2025
DONATIONS
Donations
1,440,921
247,171
1,688,092
GRANTS
Grants
37,980
37,980
1,478,901
247,171
1,726,072
Unrestricled
Funds
Restricled Total Funds
Funds
2024
DOLYATIOP4S
Donations
1,292,572
282,9JO
1,575,502
GRANTS
Grants
19,166
19,166
1,311,738
282,930
1,594,668
ANALYSIS OF GRANTS RECEIVED
Donations r¢¢¢iv¢d, includ¢d in the abo￿¢, ar¢ as follows..
2025
2024
Spe¢ial case fund
247,171
282.930
INVESTMENT INCOME
Unrestricted Total Funds Unrestricted Total Funds
Funds
2025
Funds
2024
Bank interest receivable
1,959
1,959
1,019
1,019
COSTS OF RAISING DONATIONS AND LEGACIES
Unrestricted Total Funds Unrestricted Total Funds
Funds
2025
Funds
2024
Fundraising costs
209,744
209,744
139,943
139,943
MARS I ANNUAL REPORT 2025
30

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿?
YEAR ENDED 31 DECEMBER 2025
EXPENDITURE ON CHARrrABLE ACTIVITIES BY FUND TYPE
Unrestricted
Funds
Restricted Total Funds
Funds
2025
Charitable activities
Support costs
1,269,960
42,910
205,189
1,475,149
42,910
1,312,870
205,189
1,518,059
Unrestricted
Funds
Restricted Total Funds
Funds
Charitable activilies
Support costs
1.071,074
40,366
318,698
1,389,772
40,366
1.111,440
318,698
1,430,lJ8
10. EXPENDITURE ON CHARITABLE ACTIVITIES BY ACTIVITY TYPE
Activities
undcrtaken
dire¢tly Support costs
Total funds
2025
Total fund
2024
Charitable activities
Govemance costs
1,475,149
30,928
11,982
1,506,077
11,982
1,413,685
16,453
1,475,149
42,910
1,518,059
1,430,138
11. ANALYSIS OF CHARITABLE ACTIVITIES
2025
2024
Charitable Activities
Grants 10 institutions
Special case fund
Medical Support
Holiday (Yom Tov) clinics
Health am'areness
Sustenance packages
Medical research
404207
106219
280282
302,722
21,428
446,897
401.430
172,413
26.899
84,141
96.486
161,506
96,030
205,189
1,475,149
1,389,772
MARS I ANNUAL REPORT 2025
31

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿?
YEAR ENDED 31 DECEMBER 2025
12. ANALYSIS OF SUPPORT COSTS
Charitable
activities
Total 2025 Total 2024
Finance costs
Govemance costs
Legal and professional fees
Depreciation
1.182
10,800
22,381
8,547
1,182
10000
22J81
8547
2.709
13,744
12.197
11,716
42,910
42,910
40,366
13. NET INCOME
Net income is stated after charging/(crediting)=
2025
2024
Depreciation of tangible fixed assets
Fees payable for the audit of the financial statements
8,547
10,800
11,716
13,744
14. STAFF COSTS
2025
2024
Wages and salaries
Social security costs
276260
6.537
261.685
4.326
282,797
266,011
The average Inonthly number of employees during the year was 29 (2024.. 27).
No salaries of £60.000 or over ￿'¢re paid during the year.
15. TRUSTEE REMUNERATION AND EXPENSES
No remuneration or oiher benefits from ¢mploym¢nt with the charity or a related entity w¢r¢ r¢¢eiv¢d
by the trustees.
MARS I ANNUAL REPORT 2025
32

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿?
YEAR ENDED 31 DECEMBER 2025
16. TANGIBLE FIXED ASSETS
Land and Fixtures and
buildings
fittings
Equipment
Totgl
Cost
At l January 2025 and
31 December 2025
187.703
45,801
69,694
303,198
Depreciation
Ai l January 2025
Charge for the year
At 31 December 2025
25,221
3,087
53,149
5,460
78,370
8,547
28,308
58,609
86,917
Carryillg amount
At 31 December 2025
187,703
187,703
17,493
20,580
11,085
16,545
216,281
224,828
At 31 Dcccmbcr 2024
17. DEBTORS
2025
2024
Other debtors
30,420
18. CASH AND CASH EQUIVALENTS
Cash and cash equivalents comprise the folloiving..
2025
2024
Cash at bank and in hand
Bank overdrafts
184,06)
{3)
184,062
197,883
197.883
19. CREDrroRS: iimounts f31lling dlle ￿￿thIn one ye3ir
2025
2024
Bank loans and overdrafts
Social security and other taxes
Other creditors
4,503
7,764
17,083
4,500
1,998
9,962
29,350
16,460
20. CREDrroRS: amounts falling due after more than one year
2025
2024
Bank loans and overdrafts
17,158
2?,221
MARS I ANNUAL REPORT 2025
33

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿?
YEAR ENDED 31 DECEMBER 2025
21. ANALYSIS OF CHARITABLE FUNDS
Unrestricted funds
Atl
January
2025
At31
Deeembcr
2025
Income Expenditure
General funds
326.559
1,480,860 (1,522.614)
284,805
Atl
January
2024
At31
Deceinber
2024
Income Expenditure
General funds
265,185
1,312,757 {1,251,38i)
326,559
Restricted fullds
Atl
January
2025
At31
December
2025
Income Expcnditurc
Restricted Fund
57,471
247,171
(205,189}
99,453
At I
January
2024
At31
December
2024
In¢ome Expenditure
Restricted Fund
282,930
(J18,698}
57,471
22. ANALYSIS OF NET ASSETS BETWEEN FUNDS
Unrestricted
FLinds
Restricted Total Funds
Funds
2fj25
Tangible fixed assets
Current assets
Creditors less than l year
Creditors greater than l year
216,281
115,032
(29,350)
(17,158)
216,281
214,485
(29J50}
(17,158}
99,453
Net 3issets
284,805
99,453
384,258
Unrestricted
Fuiids
Restricted Total Funds
Funds
2024
Tangible fixed assets
Current assets
Creditors less than l year
Creditors greater than l year
Net asset5
224,828
140,412
(16.460)
(22.221)
326,559
224,8?8
197,883
(16,460)
{22.221)
57,471
57,471
384,030
MARS I ANNUAL REPORT 2025
34

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20
MARS ORG. LTD
COMPANY LIMITED BY GUARANTEE
NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿?
YEAR ENDED 31 DECEMBER 2025
23. ANALYSIS OF CHANGES IN NET DEBT
At
At
l Jan 2025 Cash flows 31 Dec 2025
Cash at bank and in hand
Bank overdrafts
Debt due within one year
Debt due after one year
197,883
(13,818)
{3)
184,065
{3}
(4,499)
(17,158)
(4.500)
{22,221)
5,063
171,162
(8,757)
162,405
24. RELATED PARTIES
There have been no related party transactions in the reporting period that require disclosure.
MARS I ANNUAL REPORT 2025
35

Docusign Envelope ID". 42E7C64E-386944C1-8361-66ED4F05CE20
MedK81A<￿aCY & Refernalserv.
THANK I
You
To our partners, supporters,
specialists and community.
One Call. Expert Support. Better Outcomes.
Medical Advocacy & Referral Service
Trustees, Annual Report 2025